CervoMed (NASDAQ:CRVO) Given “Buy” Rating at D. Boral Capital

CervoMed (NASDAQ:CRVO)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $31.00 target price on the stock.

Other analysts have also issued research reports about the stock. Zacks Research upgraded shares of CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Brookline Capital Acquisition upgraded shares of CervoMed to a “strong-buy” rating in a report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, January 21st. Cantor Fitzgerald began coverage on CervoMed in a research note on Thursday, December 18th. They issued an “overweight” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of CervoMed in a research note on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CervoMed presently has a consensus rating of “Moderate Buy” and an average price target of $22.17.

CervoMed Stock Performance

CervoMed stock traded up $0.04 during trading on Wednesday, reaching $4.05. 80,540 shares of the company’s stock were exchanged, compared to its average volume of 87,374. CervoMed has a 52-week low of $1.92 and a 52-week high of $16.94. The firm has a market cap of $37.46 million, a price-to-earnings ratio of -1.40 and a beta of -0.77. The company’s 50-day moving average is $6.08 and its two-hundred day moving average is $7.59.

Institutional Investors Weigh In On CervoMed

Several large investors have recently added to or reduced their stakes in CRVO. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of CervoMed by 8,425,900.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 84,260 shares of the company’s stock valued at $666,000 after acquiring an additional 84,259 shares during the period. Jane Street Group LLC acquired a new position in CervoMed during the 2nd quarter valued at about $414,000. Citadel Advisors LLC acquired a new position in CervoMed during the 3rd quarter valued at about $247,000. Savvy Advisors Inc. bought a new position in CervoMed in the 3rd quarter worth about $210,000. Finally, AQR Capital Management LLC acquired a new stake in shares of CervoMed in the first quarter valued at approximately $227,000. 25.15% of the stock is owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.